This is one of those smaller caps that receives little coverage...

This is one of those smaller caps that receives little coverage besides one broker who has a strong buy on it. Very modest impact from Covid-19, good cashflow, very solid fully franked dividend, payout ratio around 77%. Perhaps other HC contributors can highlight some downsides.

The company has a very progressive policy re promotion of women - they have some outstanding people working for them. I'm surprised it flies so low under the radar. I think one of the difficulties is that of perception, investors thinking that patents come a long every now and then for a tech gadget whereas intellectual property involves registration and protection of all sorts of developments, including all the biomedical advances that are growing every day.